LifeSciences BC > News > Member Announcements

CDRD Appoints Wendy Hurlburt & William Charnetski to its Board of Directors

January 17, 2019

Vancouver, Canada: CDRD, Canada’s national life sciences venture, is pleased to announce the appointments of Ms. Wendy Hurlburt and Mr. William Charnetski as new Directors of the organization. Wendy Hurlburt, an executive with more than 20 years of global finance, operations and compliance experience in the healthcare and technology sectors, has held leadership positions in … Continue reading CDRD Appoints Wendy Hurlburt & William Charnetski to its Board of Directors

Phoenix Molecular Designs Announces Collaboration To Develop Diagnostic for Triple-Negative Breast Cancer

January 16, 2019
Phoenix Molecular Designs

-Diagnostic can detect activated RSK2, a prime target in TNBC, in breast cancer patients- VANCOUVER, British Columbia and SAN DIEGO, Jan. 16, 2019 /PRNewswire/ — Phoenix Molecular Designs (PhoenixMD), a privately-held biotechnology company designing precise cancer therapeutics by targeting essential kinases, announced that it has entered into a collaboration with Roche to develop a diagnostic (CDx) in triple-negative breast cancer … Continue reading Phoenix Molecular Designs Announces Collaboration To Develop Diagnostic for Triple-Negative Breast Cancer

Takeda’s global acquisition of Shire creates an expanded Takeda Canada to bring better health and a brighter future to Canadians

January 15, 2019
Takeda Canada Inc

Takeda in Canada headed by General Manager Gamze Yüceland An expanded footprint positions Takeda to provide innovative treatments for Canadians with gastrointestinal illnesses, cancer, neurological conditions and rare diseases OAKVILLE, ON, Jan. 10, 2019 /CNW/ – The global acquisition by Takeda of Shire has been completed and with it comes the creation of an expanded Takeda Canada organization that unites the … Continue reading Takeda’s global acquisition of Shire creates an expanded Takeda Canada to bring better health and a brighter future to Canadians

Quark Venture Inc. and GF Securities Participate in Keros Therapeutics’ $23 million Series B Financing for Development of Therapies to Treat Debilitating Neuromuscular Diseases

January 7, 2019
Quark Venture Inc.

Vancouver, BC – January 7, 2018 – Quark Venture Inc. (Quark) and GF Securities are pleased to announce their investment in Keros Therapeutics, a company dedicated to the discovery and development of novel therapeutics for neuromuscular diseases. The investment, made through their Global Health Sciences Fund (GHS) is part of the $23 million Series B … Continue reading Quark Venture Inc. and GF Securities Participate in Keros Therapeutics’ $23 million Series B Financing for Development of Therapies to Treat Debilitating Neuromuscular Diseases

Xenon Pharmaceuticals Outlines 2019 Key Milestones

January 7, 2019
Xenon Pharmaceuticals Inc.

Innovative Product Pipeline Includes Multiple Neurology-Focused Products Anticipated to be in Phase 2 or Later Stage Development in 2019 BURNABY, British Columbia, Jan. 06, 2019 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today provided a corporate update and outlined its anticipated key milestone events in 2019. Dr. Simon Pimstone, Xenon’s … Continue reading Xenon Pharmaceuticals Outlines 2019 Key Milestones

Phyton Biotech Partners with Agenus to Revolutionize QS-21 Production

January 3, 2019

Agenus’ R&D Project Funded by Bill & Melinda Gates Foundation Employs PCF® Technology for Potent Vaccine Ingredient FORT WORTH, Texas, January 3, 2019 – Phyton Biotech today announced an exclusive partnership with Agenus Inc. to develop an alternative manufacturing process for QS-21 to ensure a sustainable supply of this key vaccine ingredient. Agenus received a … Continue reading Phyton Biotech Partners with Agenus to Revolutionize QS-21 Production

Canada’s Digital Technology Supercluster officially launches with $153M in funding from the Ministry of Innovation, Science and Economic Development and funding commitments of over $200M from members

December 5, 2018
Canada’s Digital Technology Supercluster

Vancouver – November 27, 2018 – Canada’s Digital Technology Supercluster is excited to announce its official launch and celebrate the funding allocation by the Ministry of Innovation, Science, and Economic Development (ISED) and funding commitments by its initial cohort of members. The Government of Canada is investing up to $950 million over five years to … Continue reading Canada’s Digital Technology Supercluster officially launches with $153M in funding from the Ministry of Innovation, Science and Economic Development and funding commitments of over $200M from members

Xenon Announces Final Results of XEN1101 Phase 1 Clinical Trial and Update on XEN901 Phase 1 Clinical Trial at the American Epilepsy Society (AES) Annual Meeting

December 3, 2018
Xenon Pharmaceuticals Inc.

XEN1101 CTA Accepted by Health Canada for Initiation of Phase 2 Clinical Trial in Adult Focal Epilepsy; U.S. IND Filing Targeted in Q1 2019 Conference Call to Discuss Xenon’s Epilepsy Programs at 9 am ET Today BURNABY, British Columbia, Dec. 03, 2018 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today … Continue reading Xenon Announces Final Results of XEN1101 Phase 1 Clinical Trial and Update on XEN901 Phase 1 Clinical Trial at the American Epilepsy Society (AES) Annual Meeting

Xenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update and Overview of Presentations at the 2018 American Epilepsy Society (AES) Meeting

November 30, 2018
Xenon Pharmaceuticals Inc.

BURNABY, British Columbia, Nov. 30, 2018 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and live audio webcast on Monday, December 3, 2018 at 9:00 am Eastern Time (6:00 am Pacific Time) to provide a corporate update and overview of the Company’s poster … Continue reading Xenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update and Overview of Presentations at the 2018 American Epilepsy Society (AES) Meeting

INSTI HIV Self Test Earns WHO Prequalification Status for Home Testing

November 28, 2018
bioLytical Laboratories Inc.

The newly WHO Prequalified INSTI HIV Self Test makes a mark as it expands into new markets VANCOUVER, BC, November 28, 2018 /CNW/ – bioLytical Laboratories, a world leader in rapid infectious disease tests, is pleased to announce that its INSTI® HIV Self Test has been Prequalified  by the World Health Organization (WHO).  INSTI, the world’s fastest home … Continue reading INSTI HIV Self Test Earns WHO Prequalification Status for Home Testing